Frederick Munschauer, MD

At the 2016 CMSC Annual Meeting, Dr. Munschauer discussed the results of three studies that used real-world data to look at relapse rates, outpatients resource use, and costs related to patients taking subcutaneous interferon beta-1a as compared with other MS therapies.



The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Next Article: